日本語版は下記をご覧ください

A Pharma Talks Interview with Yo (Max) Amakusa, CEO of iBody

1. The evolution of iBody

Jens Kurth: iBody initially focused on therapeutic antibodies before successfully expanding into diagnostic antibodies. What led to this strategic shift, and what opportunities did you see that others perhaps overlooked?

Amakusa-san: Initially, our goal was to use our proprietary antibody discovery platform to develop our own therapeutic antibodies. We continue to explore opportunities in therapeutics today, but along the way, our rabbit antibody discovery technology began attracting strong interest from diagnostic companies and bioanalytics researchers, who consistently need highly functional antibodies for product development and analytical applications.

In particular, we found strong demand for antibodies that can distinguish very subtle molecular differences—such as small-molecule antigens, single amino acid mutations, and phosphorylation—with both extremely high specificity and affinity. These characteristics are particularly valuable in diagnostic and detection applications. Recognizing this opportunity, we actively expanded our business into diagnostics and bioanalytics, where the strengths of our technology can directly address unmet needs.

2. Diagnostic Antibodies

Jens Kurth: How do you see the role of diagnostic antibodies evolving over the next five to ten years?

Amakusa-san: I believe diagnostic antibodies will become more sensitive, more specific, and more versatile.

Today, many diagnostic tests focus on detecting a single biomarker. In the future, I think we will see more multiplex testing, where several biomarkers are measured at the same time.

Diagnostics will also move closer to patients through point-of-care and rapid testing.

As diagnostics become more advanced, the performance of the antibody itself will become even more important. Better antibodies will enable faster, more accurate, and more informative diagnostics.

3. Precision Medicine

Jens Kurth: As precision medicine continues to evolve, where do you believe diagnostic antibodies will have the greatest clinical impact?

Amakusa-san: I believe the greatest impact will be in selecting the right treatment for each patient.

Patients with the same disease may respond very differently to the same treatment. Diagnostic antibodies can help identify specific biomarkers that tell us which patients are most likely to benefit from a particular therapy.

They can also help monitor how a patient is responding to treatment and detect changes in the disease over time.

So, I see diagnostic antibodies becoming an important bridge between diagnosis and treatment — helping us move toward the right treatment for the right patient at the right time.

4. Japan vs Europe

Jens Kurth: Having built iBody in Japan, what differences do you see between the Japanese and European innovation ecosystems?

Amakusa-san: One difference I see is the role of regional biotech clusters.

In Europe, biotech clusters are very active, and companies, universities, investors, and other organizations are well connected within each region.

At the same time, because European countries are geographically close and well connected, these networks can easily expand across borders. A company in Belgium, for example, can naturally work with partners in France, Germany, Switzerland, or other countries.

In Japan, we tend to build the ecosystem mainly within Japan. Europe, on the other hand, has a strong advantage in building cross-border ecosystems and looking at the European market as a whole.

I think this creates more opportunities for collaboration and makes it easier for biotech companies to think internationally from an early stage.

5. Partnering

Jens Kurth: What makes a pharmaceutical or diagnostics company an attractive partner for iBody?

Amakusa-san: iBody is an antibody discovery technology company. We do not have our own therapeutic or diagnostic targets.

So, for us, the ideal partner is a company whose strengths complement ours. Our partners bring their targets, disease knowledge, and development expertise, while we bring our antibody discovery technology.

The goal can be either drug discovery or diagnostic development. Both are important to us.

Most importantly, we want to build long-term partnerships. Rather than working together on just one project, we want to contribute to the development of many products over time.

I believe the best partnerships are those where both sides bring different strengths and create value together.

6. Lessons learned

Jens Kurth: Looking back over the past years as CEO, what has been your biggest lesson in building strategic partnerships?

Amakusa-san: The biggest lesson I have learned is that a strong partnership must create value for both sides.

A good example is our strategic capital and business partnership with TAUNS, a Japanese diagnostics company.

We contribute to their product development through our antibody discovery technology. At the same time, their investment allows us to further improve our technology and strengthen our business.

As our technology becomes stronger, we can create even more value for TAUNS and other partners.

So, for me, the best partnership is not simply about exchanging technology or money. It is about creating a win-win relationship where both companies can grow together over the long term.

7. Innovation

Jens Kurth: What trends in antibody discovery or diagnostics excite you most today?

Amakusa-san: AI is a topic we hear about everywhere today, but I am very excited about its potential in antibody discovery.

We have already started feasibility studies to combine AI with our experimental antibody discovery approach.

By combining AI-based prediction and design with our experimental technology, we believe we can discover better and more valuable antibodies.

Ultimately, our goal is not simply to use AI. Our goal is to use the best combination of AI and experimental approaches to improve and accelerate the development of new therapeutics and diagnostics.

8. Leadership

Jens Kurth: How do you balance scientific excellence with commercial execution?

Amakusa-san: One of the unique strengths of iBody is the combination of science and business.

iBody was founded by scientists, and I later joined the company with many years of business experience.

My role is to translate the scientific value created from university research into services and messages that the market can understand, and ultimately into real value for society.

By bringing our technology into real-world drug and diagnostic development, we gain experience, learn from our partners, and continuously improve and refine our technology.

I believe an important role of leadership is to create this positive cycle: great science creates real-world value, and real-world experience makes the science even better.

9. Europe

Jens Kurth: Why is Europe strategically important for iBody’s future?

Amakusa-san: Europe is strategically very important for iBody because it has a strong ecosystem in both pharmaceutical and diagnostic development.

There are many world-leading pharmaceutical and diagnostic companies, innovative biotech companies, and excellent research institutions across Europe.

For iBody, Europe is not simply a market where we want to sell our antibody discovery services. We want to build strong partnerships and become part of the European innovation ecosystem.

By working closely with European partners we can bring our antibody discovery technology into more drug and diagnostic development programs, learn from those collaborations, and continue to improve our technology.

So, Europe is an important part of our long-term global growth strategy.

10. Advice

Jens Kurth: What advice would you give entrepreneurs building innovative life science companies today?

Amakusa-san: My advice is: don’t focus only on your technology.

In life science, we often start with great science or innovative technology. But great technology alone does not create a successful company.

You need to understand what real problem your technology can solve, who needs it, and how you can deliver that value to them.

It is also very important to listen to customers and partners. Their feedback can help you improve not only your business, but also your technology.

So, my advice is to go outside the lab, talk to people, and test your ideas in the real world as early as possible.

Great science is the starting point. Turning it into real value is what builds a company.

Closing question

„Looking back over your career, what is one lesson you wish you had learned much earlier about building international collaborations?“

If I could go back, I would start building international relationships much earlier.

Especially since the COVID pandemic, online meetings have become a normal part of business. They are very useful, but I have learned that face-to-face communication is still extremely important.

And it is not enough to meet someone just once. Meeting people again and again, visiting their companies, and spending time together builds a much deeper level of trust.

I have learned that international collaboration is not created simply by having good technology or a good business proposal. In the end, it is built on trust between people.

Once that trust is established, new opportunities often come naturally, sometimes in ways you never expected.

So, if I could give my younger self one piece of advice, it would be: go out into the world, meet people face-to-face, and keep building those relationships over time.

The interview took place on 27 August 2026.

---

抗体イノベーションを社会における真の価値へ

Pharma Talks インタビュー：iBody CEO Yo (Max) Amakusa（天草）氏に聞く

1. iBodyの進化

iBodyは当初、治療用抗体に注力していましたが、その後、診断用抗体の分野にも展開し、成功を収めています。この戦略的な展開の背景には何があったのでしょうか。また、他社が見落としていたかもしれない、どのような可能性を見出したのでしょうか？

天草さん:

はい、当初は自社の優れたプラットフォームを用いた創薬を目指していました。もちろん現在も創薬の可能性は追い続けていますが、当社のウサギ抗体探索は、製品開発に常に高機能な抗体を必要とする診断薬企業やバイオアナリティクスの研究者から注目をあつめるようになりました 。特に低分子抗原や1アミノ酸変異、リン酸化に極めて特異的で親和性も高い抗体は診断、検出用のニーズが高いことが分かり積極的な事業展開を行いました。

2. 診断用抗体

今後5〜10年で、診断用抗体の役割はどのように変化していくと考えていますか？

天草さん:
今後、診断用抗体は、より高感度、高特異性になり、さらに幅広い用途で使われるようになると考えています。

現在、多くの診断検査では単一のバイオマーカーを検出していますが、将来は複数のバイオマーカーを同時に測定するマルチプレックス検査が増えていくでしょう。

また、ポイント・オブ・ケア検査や迅速検査によって、診断はより患者さんに近い場所で行われるようになると思います。

診断技術が高度になるほど、抗体そのものの性能がさらに重要になります。より良い抗体が、より迅速で正確、そしてより多くの情報を提供できる診断を可能にすると考えています。

3. プレシジョン・メディシン（精密医療）

プレシジョン・メディシンが進展していく中で、診断用抗体はどの領域で最も大きな臨床的インパクトをもたらすと考えていますか？

天草さん：
最も大きなインパクトがあるのは、患者さん一人ひとりに適した治療を選択することだと考えています。

同じ病気の患者さんでも、同じ治療に対する反応は大きく異なることがあります。診断用抗体によって特定のバイオマーカーを検出することで、どの患者さんが特定の治療から最も効果を得られる可能性が高いかを判断できるようになります。

また、治療に対する患者さんの反応をモニタリングしたり、時間とともに起こる病気の変化を捉えたりすることにも役立ちます。

つまり、診断用抗体は診断と治療をつなぐ重要な橋渡しになっていくと思います。

4. 日本と欧州

日本でiBodyを成長させてきた経験から、日本と欧州のイノベーション・エコシステムにはどのような違いがあると感じていますか？

天草さん:

私が感じる違いの一つは、地域のバイオクラスターが果たしている役割です。

欧州ではバイオクラスターが非常に活発で、それぞれの地域で企業、大学、投資家、その他の組織が密接につながっています。

同時に、欧州の国々は地理的に近く、互いにつながっているため、こうしたネットワークが国境を越えて広がりやすいと感じます。例えばベルギーの企業が、フランス、ドイツ、スイスなどのパートナーと自然に連携することができます。

日本では、エコシステムを主に日本国内で構築する傾向があります。一方、欧州には、国境を越えたエコシステムを構築し、欧州市場全体を一つのマーケットとして捉えやすいという大きな強みがあります。

その結果、コラボレーションの機会が増え、バイオテック企業が早い段階から国際的な視点を持ちやすいのではないかと思います。

5. パートナーシップ

iBodyにとって、魅力的なパートナーとなる製薬企業や診断薬企業とは、どのような企業でしょうか？

天草さん：

iBodyは抗体探索技術の会社です。私たちは自社で治療や診断のターゲットを持っているわけではありません。

そのため、私たちにとって理想的なパートナーは、お互いの強みが補完関係になる企業です。パートナーはターゲットや疾患に関する知識、開発力を持ち、私たちは抗体探索技術を提供します。

その目的は、創薬でも診断薬開発でも構いません。どちらも私たちにとって重要です。

そして最も重要なのは、長期的なパートナーシップを築くことです。一つのプロジェクトだけで終わるのではなく、長期にわたって多くの製品開発に貢献していきたいと考えています。

私は、お互いが異なる強みを持ち寄り、一緒に新しい価値を生み出せる関係こそ、最も良いパートナーシップだと考えています。

6. これまでに学んだこと

CEOとしてこれまでを振り返ったとき、戦略的パートナーシップを構築するうえで最も大きな学びは何でしたか？

天草さん：

私が学んだ最も大きなことは、強いパートナーシップは、双方に価値を生み出すWin-Winの関係でなければならないということです。

その良い例が、日本の診断薬企業であるTAUNSとの戦略的な資本業務提携です。

私たちは抗体探索技術によってTAUNSの製品開発に貢献しています。一方で、TAUNSからの出資によって、私たちはさらに技術を高め、事業を強化することができます。

そして私たちの技術がさらに強くなれば、TAUNSをはじめとするパートナーに、より大きな価値を提供できるようになります。

ですから私にとって理想的なパートナーシップとは、単に技術や資金を交換する関係ではありません。お互いが価値を生み出し、長期的に一緒に成長していけるWin-Winの関係だと考えています。

7. イノベーション

現在、抗体探索や診断分野において、最も期待している、あるいはワクワクしているトレンドは何ですか？

天草さん：

AIは現在、あらゆるところで非常によく話題になるテーマですが、私は抗体探索におけるAIの可能性に非常に期待しています。

私たちはすでに、AIと当社の実験的な抗体探索アプローチを組み合わせるためのフィージビリティスタディを開始しています。

AIによる予測や設計と、私たちの実験技術を組み合わせることで、より優れた、より価値の高い抗体を発見できると考えています。

最終的な目的は、単にAIを使うことではありません。AIと実験的アプローチを最適に組み合わせることで、新しい治療薬や診断薬の開発をより良いものにし、さらに加速することが私たちの目標です。

8. リーダーシップ

科学的な卓越性と、ビジネスとして成果を出すことを、どのように両立していますか？

天草さん：

iBodyのユニークな強みの一つは、科学とビジネスの組み合わせです。

iBodyは科学者によって創業され、そこに長年のビジネス経験を持つ私が後から加わりました。

私の役割は、大学発の研究から生まれた科学的な価値を、市場に理解されるサービスやメッセージに変換し、最終的に社会に実際の価値として届けることです。

そして、私たちの技術を実際の創薬や診断薬開発の現場で使うことで、経験を積み、パートナーから学び、技術そのものを継続的に高度化、洗練していくことができます。

私は、このプラスの循環を生み出すことが、リーダーとして重要な役割だと考えています。

「優れた科学が社会での価値を生み、社会での実践経験が科学をさらに良くする。」

9. 欧州

iBodyの将来にとって、なぜ欧州が戦略的に重要なのでしょうか？

天草さん：

欧州は、医薬品と診断薬の両方で非常に強いエコシステムを持っているため、iBodyにとって戦略的に非常に重要です。

欧州には、世界をリードする製薬企業や診断薬企業、革新的なバイオテック企業、そして優れた研究機関が数多く存在しています。

iBodyにとって欧州は、単に抗体探索サービスを販売したい市場ではありません。強いパートナーシップを構築し、欧州のイノベーション・エコシステムの一員になりたいと考えています。

欧州のパートナーと密接に連携することで、私たちの抗体探索技術をより多くの創薬・診断薬開発プログラムに活用し、そこから学び、さらに技術を高めていくことができます。

その意味で、欧州はiBodyの長期的なグローバル成長戦略において重要な地域だと考えています。

10. アドバイス

現在、革新的なライフサイエンス企業を立ち上げ、成長させようとしている起業家に、どのようなアドバイスをしますか？

天草さん：

私からのアドバイスは、自分たちの技術だけに集中しすぎないことです。

ライフサイエンスでは、優れた科学や革新的な技術から事業が始まることが多いと思います。しかし、優れた技術があるだけでは、会社を成功させることはできません。

その技術が実際にどのような課題を解決できるのか、誰がそれを必要としているのか、そして、その価値をどうやって届けるのかを理解する必要があります。

また、顧客やパートナーの声を聞くことも非常に重要です。そのフィードバックによって、ビジネスだけでなく、技術そのものもさらに良くすることができます。

ですから、できるだけ早く研究室の外に出て、人と話し、自分たちのアイデアを実際の世界で試してみることをおすすめします。

「優れた科学はスタート地点。その科学を本当の価値に変えることが、会社をつくる。」

最後の質問

これまでのキャリアを振り返って、国際的なコラボレーションを構築するうえで、「もっと早く知っておきたかった」と思うことを一つ挙げるとしたら、何でしょうか？

天草さん：

もし過去に戻れるなら、もっと早く国際的な人間関係を築き始めたかったと思います。

特にコロナ禍以降、オンラインミーティングはビジネスにおいて当たり前になりました。もちろん非常に便利ですが、それでも私は、対面でのコミュニケーションが非常に重要だということを学びました。

そして、一度会うだけでは十分ではありません。何度も顔を合わせ、相手の会社を訪問し、一緒に時間を過ごすことで、より深い信頼関係が生まれます。

国際的なコラボレーションは、単に良い技術や良いビジネス提案があれば生まれるものではありません。結局のところ、その基盤にあるのは人と人との信頼関係です。

一度その信頼関係ができると、そこから新しい機会が自然に生まれ、ときにはまったく予想していなかった展開につながることもあります。

だから、もし若い頃の自分に一つだけアドバイスできるなら、

「世界に出て、直接人に会い、そして時間をかけてその関係を築き続けろ」

と言いたいです。

インタビューは2026年8月27日に実施されました。

A Conversation with Dr. Bettina Ernst on Biotech Investing, Company Building and the Future of Innovation

26 August 2026

The Investment Landscape

Pharma Talks: The biotech investment environment has changed significantly over the past decade. From your perspective, what are the most important changes in how investors evaluate opportunities today?

Dr. Bettina Ernst:

“I think the years leading up to and during COVID created a bubble. There was simply too much money invested in biotechnology, and in many cases capital flowed into companies that probably were not yet investable. We saw IPOs at extremely high valuations, but the same was true for private companies. Even in Switzerland, early-stage valuations reached levels that, in hindsight, were simply too high.

That inevitably led to a correction. Unfortunately, some companies had to disappear, even though their science was excellent. It was a painful correction, but probably a necessary one. I also believe we are still living with the consequences of that period.

Today it is still very difficult to finance biotechnology companies, particularly in the early stages. Clinical-stage companies may find it somewhat easier, but overall the financing environment remains very challenging. Companies therefore need to be much more open to partnerships and much more creative in finding ways to move their assets forward.”

Pharma Talks: I completely agree. We see exactly the same development. Even though new funds continue to emerge, investors are looking much more carefully at the risks today. Can the programme really be developed? Can it reach the clinic? How strong is the intellectual property? Compared with six or seven years ago, it has clearly become much more selective.

Dr. Bettina Ernst:

“Exactly. I often describe the COVID years as the golden years for biotechnology. COVID created an enormous wave of innovation, but eventually every bubble is followed by a correction. That is simply what happened.”

Science versus Execution

Pharma Talks: Outstanding science is essential, but it is rarely sufficient on its own. What distinguishes a scientifically exciting project from a company you would seriously consider investing in?

Dr. Bettina Ernst:

“For me, science is non-negotiable. Without outstanding science there is no biotechnology company. But execution is equally non-negotiable.

Scientific founders are often exceptional researchers, but they are not necessarily experts in development or execution. That is perfectly acceptable. What matters is that they recognise this and are willing to strengthen their management team with people who can take responsibility for development and execution.

Without proper execution, even the best science will never fulfil its potential.

I recently had the opportunity to speak with the Hong Kong Secretary for Health and one point came up during that discussion that has stayed with me ever since. We were talking about Switzerland being recognised as one of the world’s most innovative countries. But innovation that never reaches the market is not really innovation. The same applies to biotechnology. The best science without proper execution ultimately creates very little value.”

Pharma Talks: I completely agree. From an investor’s perspective, how do you assess execution? It is obviously much harder to evaluate than the science itself.

Dr. Bettina Ernst:

“One thing I find very valuable is to follow management teams over a period of time before making an investment. Founders will often explain what they plan to achieve over the next six months. When you meet them again, you can see whether they have actually delivered what they originally promised.

Of course, plans change. Companies sometimes need to pivot because experiments don’t work or because they discover a better solution. That is completely normal.

What matters is how they progress, how they think, how they communicate and whether they continue moving the company forward. That tells you a great deal about their ability to execute.”

The Founding Team

Pharma Talks: The founding team is another aspect you have already touched on, and it seems to be absolutely critical. How much importance do you place on the founders themselves when making an investment decision?

Dr. Bettina Ernst:

“There are different philosophies among investors. Some venture capital firms prefer to put the founding team together themselves. They identify the science, bring in experienced entrepreneurs and essentially build the company around the technology. There are certainly pros and cons to that approach.

Personally, however, I very much like founder-led companies, especially when the founder has spent ten years or more working on the underlying science. If somebody has dedicated that much time to one scientific question, they usually have an exceptional understanding of the biology. More importantly, they have already demonstrated perseverance. They have believed in the science for many years and have continued despite setbacks and uncertainty.

Founders who have spent many years developing the underlying science usually believe deeply in their programme because they know it inside out. I think scientific founders often have much greater resilience than a serial entrepreneur who is brought in by a venture capital firm. If things don’t work out, a professional manager can simply move on to the next opportunity because the emotional attachment is very different.

Of course, founders can also become too emotionally attached to their programme. That is where investors have an important role. They need to help founders remain objective, establish a realistic development plan and recognise when something needs to change.

If somebody has spent ten years developing a programme in an academic environment, they have usually had enough time to understand whether the underlying scientific concept is really robust. After that, the challenge becomes execution.”

Pharma Talks: I fully agree. I see something very similar in my own work with scientists. They are naturally focused on the science, whereas we immediately start talking about intellectual property, freedom to operate and how the programme can ultimately be translated into a company. It is a very interesting transition.

Dr. Bettina Ernst:

“Exactly. At that stage the discussion shifts from science to execution.”

Early Red Flags

Pharma Talks: What are the early red flags that make you decide not to invest in a company?

Dr. Bettina Ernst:

“One of the biggest red flags for me is a lack of transparency. If founders are not prepared to openly share their data, discuss the science honestly or talk about risks and experiments that may not have produced the expected results, that immediately raises concerns. Transparency and open communication are absolutely essential.

Another important red flag is the absence of a clear development plan. Founders need to have the end in mind from the very beginning. They should understand the patient population, the clinical pathway, whether the trial is feasible, whether manufacturing is manageable and what the cost of goods might ultimately look like. In other words, they need to understand the whole picture.

The competitive landscape is equally important. If founders do not know how their programme compares with existing approaches or where it fits into the market, that is another significant warning sign.

Finally, I always like to see clearly defined de-risking milestones, or value-inflection points. At every stage of development there should be one critical experiment that answers an important question and significantly reduces uncertainty. Those milestones can often be defined before development even starts. Of course, plans will evolve and companies may need to pivot, but founders should already have thought through this process before they ask investors for money.

As an investor, I want to see that founders not only have a development plan, but that they truly understand it, believe in it and are committed to executing it.”

Pharma Talks: I completely agree. That is actually something I spend a lot of time working on as well, helping founders think backwards from the end of development, understand the medical need, define the competitive landscape and identify what is really required to move a programme forward.

Dr. Bettina Ernst:

“Exactly. That kind of preparation makes a tremendous difference.”

Leadership

Pharma Talks: Another point that I find very interesting is leadership. Founders naturally become CEOs when the company is created, but at some point the company changes. From an investor’s perspective, do founders need to recognise that there may come a stage where someone else should lead the company?

Dr. Bettina Ernst:

“I think that is a discussion that should happen much earlier than it usually does.

Sometimes founders feel that because they started the company they also have to remain CEO throughout the entire journey. I don’t think that is necessarily the right approach.

I have seen an excellent example where a founder stepped back into the role of Chief Scientific Officer while an experienced CEO was brought in. At the same time, the founder worked closely with an outstanding chairman who acted as a mentor over the following years. Eventually, he grew into the CEO role himself.

Looking back, I think that was probably the best possible outcome, both for the individual and for the company.

Building a biotechnology company is a long journey, and leadership requirements change over time. A certain degree of flexibility is extremely valuable, even though it is not always an easy discussion to have.”

Value Creation

Pharma Talks: Looking across the companies you have worked with, what differentiates those that consistently create value from those that struggle despite promising science? That’s something I see quite often as well. Companies have excellent science, but they don’t really know how to translate it into preclinical development, into the clinic, or even which patients and indications they should focus on.

Dr. Bettina Ernst:

“I think it all comes back to having a very clear development plan and a realistic understanding of the resources required to execute it. Companies need to stay focused and avoid doing science simply for the sake of doing science. They also need financial discipline and should carefully consider how they spend their money. Building a large laboratory, for example, is not always the best use of limited resources at an early stage.

Ultimately, it comes back to having a clear development plan, maintaining focus and using resources in a disciplined way. Companies need to understand exactly what they want to achieve, how they are going to get there and what resources are required to reach each milestone.”

Pharma Talks: Do you also think the choice of indication is critical? I have seen companies deliberately choose large indications because they appeared to offer the greatest commercial opportunity. From your perspective, is the largest indication always the right place to start?

Dr. Bettina Ernst:

“Yes, I think that happens quite often, and unfortunately it is not only management teams that make that mistake. Boards sometimes make the same decision because they naturally focus on large markets with a high unmet medical need.

However, I think companies should carefully consider whether the first indication is really the right one. Sometimes it is much more sensible to choose a smaller indication where the clinical development pathway is feasible and where the company can reach a meaningful clinical endpoint relatively quickly. Once that proof of concept has been established, it becomes much easier to attract investors and expand into larger indications later.

The first indication should create value by demonstrating that the technology works. That is often a much better strategy than trying to tackle the largest market from the very beginning.”

Europe – Future

Pharma Talks: Europe continues to produce outstanding science, yet relatively few biotechnology companies become global leaders. From your point of view, what are the biggest barriers?

Dr. Bettina Ernst:

“I actually think the European biotechnology ecosystem has improved significantly over the past twenty years. One of the biggest changes has been the emergence of serial entrepreneurs who are now building their second or third companies. That experience is extremely valuable and is gradually strengthening the ecosystem.

At the same time, Europe is still very different from the United States. If you look at Boston, San Diego or the San Francisco Bay Area, you simply find a much larger biotechnology industry. There is easier access to venture capital, there is a much larger pool of experienced talent and there are many more opportunities to recruit people who have already built successful companies.

Investors are also naturally more comfortable investing in companies that are part of those established ecosystems.

On the other hand, I also see experienced people returning to Europe, and I think that is very positive. Europe has excellent science and outstanding universities. The scientific foundation is there. The challenge is to continue building the entrepreneurial experience that allows more of this science to develop into globally successful biotechnology companies.

The US biotechnology industry is still considerably larger than Europe’s, and that is simply the reality today.”

Pharma Talks: Do you think Europe primarily needs more venture capital, or does it need more experienced founders and executives who have already built biotechnology companies before?

Dr. Bettina Ernst:

“It clearly takes both. Capital alone is not enough if it is not deployed wisely. Experience is what helps ensure strong judgement, disciplined execution and the effective use of that capital.”

The Next Decade

Pharma Talks: Europe continues to produce outstanding science, but relatively few biotechnology companies become global leaders. Looking ahead, where do you see the greatest opportunities in biotechnology over the next five to ten years?

Dr. Bettina Ernst:

“I think there are several areas that are particularly exciting. One is certainly the shift we are seeing in cell therapy. For example, in CAR-T, there is increasing interest in moving from ex vivo approaches towards in vivo technologies. If we can eventually achieve the same outcome directly in the patient, these therapies could become much more accessible and easier to deliver.

I have also seen fascinating developments in completely different areas such as regenerative medicines, neuroscience and neurodegenerative diseases.

Another interesting example I recently came across is the production of platelets from cell lines. If that becomes feasible on a larger scale, we may become much less dependent on blood donations. These are developments that, only a few years ago, would have sounded almost like science fiction.”

Pharma Talks: I also think monitoring and biomarkers will become increasingly important. There are already companies using next-generation sequencing together with artificial intelligence to identify mutations that could indicate a future disease risk and then monitor those individuals over time. AI seems to be becoming an important part of that process.

Dr. Bettina Ernst:

“I completely agree. I think biomarkers, digital technologies and continuous monitoring will become increasingly important. The interesting question is whether we will eventually be able to monitor health in such a way that intervention becomes possible much earlier, perhaps even before a disease develops.

That immediately raises another question. Will reimbursement systems evolve as well? Today, reimbursement is generally linked to treating an established disease. In the future, could healthcare systems also reimburse interventions that prevent disease before symptoms appear? I think these discussions have already started and will become increasingly important.”

Pharma Talks: That is certainly a fascinating development.

Dr. Bettina Ernst:

“Another area that I personally find extremely interesting is the regulatory genome, including long non-coding RNAs. In my view, this field has the potential to fundamentally change the way we understand biology and disease

If these approaches can be successfully translated into medicines, they may allow us to modulate pathological cellular programmes by targeting regulatory mechanisms that have traditionally been considered difficult to address.

It is still an early field, and its clinical potential remains to be demonstrated. However, if successful, it could represent an important new therapeutic modality and may ultimately prove as transformative as some of the major therapeutic innovations introduced over previous decades.”

Advice to Founders

Pharma Talks: What kind of advice would you give first-time founders before they approach investors?

Dr. Bettina Ernst:

“My advice would be to develop a very clear development plan before raising capital. Founders should have the end in mind from the very beginning. They need to understand the de-risking milestones, the key clinical experiments, the amount of capital that will be required and the overall development strategy.

That also means understanding the indication, the feasibility of the clinical trial, the endpoints that need to be achieved, the biomarkers required for patient selection and, increasingly, the manufacturing strategy. CMC has been underestimated for many years, but today it has become a critical element of successful product development.

Investors want to see that founders have thought through the entire journey before they ask for funding. The science may be excellent, but it needs to be supported by a realistic development strategy.”

Pharma Talks: I completely agree. Manufacturing and CMC have become much more important than they were a few years ago.

Dr. Bettina Ernst:

“Absolutely. They have been underestimated for a long time, but today they are an essential part of building a successful biotechnology company.

Pharma Talks: Looking back at all the companies you’ve worked with, what is the one lesson you wish every first-time founder understood before raising their first financing round?

Dr. Bettina Ernst:

My central advice would be: Do not simply raise money to continue the work. Raise enough money to answer a question that materially changes the value and future of the company.”

Final Question

Pharma Talks: Can great execution compensate for average science? Or can outstanding science compensate for poor execution?

Dr. Bettina Ernst:

I think the science always needs to be solid. There is no substitute for good science.

At the same time, outstanding execution can create tremendous value, even when the innovation itself is more incremental than revolutionary. If you look at many of the assets coming out of China, for example, they are often not completely novel, but they are developed with remarkable discipline and speed. The execution is outstanding.

The opposite is much more difficult. Outstanding science alone cannot compensate for poor execution.

Ultimately, successful biotechnology companies need both, strong science and excellent execution.

The interview took place on 15 July 2026.